Navacims for systemic lupus erythematosus (Parvus Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameNavacims for systemic lupus erythematosus (Parvus Therapeutics)
Drug Alias Namenanoparticles for systemic lupus erythematosus (Parvus Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionT lymphocytes modulators
TargetsUpdating
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesParvus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesParvus Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A